In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

WaferGen completes $30.6mm private placement

Executive Summary

WaferGen Biosystems Inc. (genomic analysis tools) has closed a $30.6mm private placement of equity and debt (issuing 2.9mm Series A-1 convertible shares, $15.275mm in promissory notes, and warrants redeemable for 56mm common shares) to Great Point Partners, Deerfield Management, Merlin Nexus, Shivji Family Trust, CIBC Trust Co., Kanter Family Foundation, Biomedical Value Fund, Biomedical Institutional Value Fund, Biomedical Offshore Value Fund, WS Investments III, Lyrical Multi-Manager Fund, Deerfield Special Situation Fund, and Deerfield Private Design Fund; certain management personnel and board members--including Robert Coradini, David Morrison, Jeffrey Jay, Paul Schimmel, and Joel Kanter--participated as well. Placement agents were Oppenheimer & Co. (lead), Madison Williams & Co., and Summer Street Research Partners.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Investment in Public Equity
    • Private Placement
    • Other

Related Companies